Literature DB >> 33774704

Do proinflammatory cytokines play a role in clozapine-associated glycometabolism disorders?

Tongtong Zhao1,2, Kai Zhang1,2, Yelei Zhang1,2, Yating Yang1,2, Xiaoshuai Ning1,2, Yu Hu1,2, Xiaoyue Li1,2, Yulong Zhang1,2, Lei Xia1,2, Zhenhua Ren3, Huanzhong Liu4,5.   

Abstract

RATIONALE AND
OBJECTIVE: Clozapine (CLZ) is the most effective drug for treatment-resistant schizophrenia but is associated with many side effects, including glycometabolism disorders. Immunological mechanisms may be involved in the development of clozapine side effects. Research relating the immunomodulatory effects of clozapine and its early markers to clinically relevant adverse events is needed to reduce the harmful side effects of clozapine. This study aimed to investigate the role of proinflammatory cytokines in clozapine-associated glycometabolism disorders.
METHODS: We measured the effect of a range of doses of clozapine on glycometabolism-related parameters and proinflammatory cytokines levels in mice peripheral blood. We also examined the differences between these indicators in the peripheral blood of clozapine-treated schizophrenia patients and healthy controls. Furthermore, we detected proinflammatory cytokines expression in mice pancreatic tissue.
RESULTS: Following clozapine administration, glucagon significantly decreased in mouse serum, and proinflammatory cytokine IL-β levels markedly increased. Clozapine reliably increased proinflammatory cytokines (IL-1β, IL-6, and TNF-α) expression in murine pancreatic tissue. Compared with healthy controls, clozapine-treated patients' BMI, blood glucose, and proinflammatory cytokines (IL-1β, IL-6, and TNF-α) increased significantly. In clozapine-treated patients, a higher clozapine daily dosage was associated with higher levels of the proinflammatory cytokines IL-1β and IL-6, and a significant positive correlation was observed between blood glucose levels and the proinflammatory cytokines IL-6 and TNF-α.
CONCLUSION: Findings from animal experiments and clinical trials have shown clear evidence that clozapine has a regulatory effect on immune-related proinflammatory cytokines and influences glycometabolism indicators.

Entities:  

Keywords:  Clozapine; Glycometabolism disorders; Immunomodulatory; Proinflammatory cytokine

Mesh:

Substances:

Year:  2021        PMID: 33774704     DOI: 10.1007/s00213-021-05824-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  51 in total

Review 1.  Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?

Authors:  David Baumeister; Simone Ciufolini; Valeria Mondelli
Journal:  Psychopharmacology (Berl)       Date:  2015-08-14       Impact factor: 4.530

2.  Effects of subchronic clozapine administration on serum glucose, cholesterol and triglyceride levels, and body weight in male BALB/c mice.

Authors:  Chih-Ya Cheng; Chen-Jee Hong; Shih-Jen Tsai
Journal:  Life Sci       Date:  2005-03-25       Impact factor: 5.037

3.  Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote glucose disposal and inflammation.

Authors:  Erez Dror; Elise Dalmas; Daniel T Meier; Stephan Wueest; Julien Thévenet; Constanze Thienel; Katharina Timper; Thierry M Nordmann; Shuyang Traub; Friederike Schulze; Flurin Item; David Vallois; Francois Pattou; Julie Kerr-Conte; Vanessa Lavallard; Thierry Berney; Bernard Thorens; Daniel Konrad; Marianne Böni-Schnetzler; Marc Y Donath
Journal:  Nat Immunol       Date:  2017-01-16       Impact factor: 25.606

Review 4.  Type 2 diabetes as an inflammatory disease.

Authors:  Marc Y Donath; Steven E Shoelson
Journal:  Nat Rev Immunol       Date:  2011-01-14       Impact factor: 53.106

Review 5.  Asymptomatic pancreatitis associated with clozapine.

Authors:  N Bergemann; C Ehrig; K Diebold; C Mundt; R von Einsiedel
Journal:  Pharmacopsychiatry       Date:  1999-03       Impact factor: 5.788

6.  Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome.

Authors:  Wouter Beumer; Roosmarijn C Drexhage; Harm De Wit; Marjan A Versnel; Hemmo A Drexhage; Dan Cohen
Journal:  Psychoneuroendocrinology       Date:  2012-04-27       Impact factor: 4.905

Review 7.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.

Authors:  Charles A Dinarello
Journal:  Blood       Date:  2011-02-08       Impact factor: 22.113

Review 8.  Atypical antipsychotics and effects on feeding: from mice to men.

Authors:  Louise Benarroch; Chantel Kowalchuk; Virginia Wilson; Celine Teo; Melanie Guenette; Araba Chintoh; Yasika Nesarajah; Valerie Taylor; Peter Selby; Paul Fletcher; Gary J Remington; Margaret K Hahn
Journal:  Psychopharmacology (Berl)       Date:  2016-06-01       Impact factor: 4.530

Review 9.  Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes.

Authors:  Jiezhong Chen; Xu-Feng Huang; Renfu Shao; Chen Chen; Chao Deng
Journal:  Front Neurosci       Date:  2017-11-21       Impact factor: 4.677

Review 10.  Targeting innate immune mediators in type 1 and type 2 diabetes.

Authors:  Marc Y Donath; Charles A Dinarello; Thomas Mandrup-Poulsen
Journal:  Nat Rev Immunol       Date:  2019-09-09       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.